Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis

Journal of Infectious Diseases

Volumn 211, Issue 8, 2015, Pages 1202-1204

  Grant, Robert M ^a,b   Liegler, Teri ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO AIDS FOUNDATION   (United States)

Author keywords

antiretroviral; drug resistance; HIV; preexposure prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEROCONVERSION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84926665838     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu678     Document Type: Note

References (19)

1. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-90.
2. Grant RM, Lama JR, Anderson PL, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
3. Baeten JM, Donnell D, Ndase P, et al. Antire-troviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367: 423-34.
5. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381:2083-90.
6. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-22.
7. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir-emtricita-bine, or vaginal tenofovir gel in the VOICE Study (MTN 003). Presented at: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 2013.
8. Lehman DA, Baeten JM, McCoy CO, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single or dual-agent pre-exposure prophylaxis. J Infect Dis. 2015; 211:1211-8.
9. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of te-nofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 2014; 66:340-8.
10. Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010; 2:14ra4.
11. Baeten JM, Donnell D, Mugo NR, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis 2014; 14:1055-64.
12. Anderson PL, Glidden DV, Liu A, et al. Em-tricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012; 4:151ra25.
13. Liegler T, Abdel-Mohsen M, Bentley LG, et al. HIV-1 drug resistance in the iPrEx pre-exposure prophylaxis trial. J Infect Dis 2014; 210:1217-27.
14. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014; 14: 820-9.
15. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re4.
16. Gandhi M, Gandhi RT. Single-pill combination regimens for treatment of HIV-1 infection. N Engl J Med 2014; 371:248-59.
17. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155-66.
18. Supervie V, Garcia-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci USA 2010; 107:12381-6.
19. Centers for Disease Control and Prevention (CDC). Preexposure prophylaxis for the prevention of HIV infection in the United States-2014: a clinical practice guideline. Atlanta, GA: CDC, 2014. http://www.cdc. gov/hiv/pdf/PrEPguidelines2014.pdf. Accessed 5 December 2014.